Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rVSV-BDBV
- Development stage
- Preclinical
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rVSV-BDBV (also known as rVSV-BDBV-GP) is an investigational live-attenuated recombinant vesicular stomatitis virus (rVSV) vector vaccine being developed by IAVI (International AIDS Vaccine Initiative) in collaboration with Hilleman Laboratories, SK bioscience, and IDT Biologika. The vaccine is designed to prevent Bundibugyo virus disease, an Ebola-type disease caused by the Bundibugyo ebolavirus (BDBV). It utilizes the same rVSV vector platform as the licensed Ervebo vaccine, but expresses the Bundibugyo virus glycoprotein (GP) instead of the Zaire ebolavirus glycoprotein. In preclinical studies in nonhuman primates, a single dose of rVSV-BDBV demonstrated high-level protective efficacy within days of vaccination. The vaccine is undergoing process development, manufacturing scale-up, and clinical evaluation supported by funding from the Biomedical Advanced Research and Development Authority (BARDA) and the Coalition for Epidemic Preparedness Innovations (CEPI), with plans for Phase 1 clinical trials and a subsequent ring vaccination trial in the Democratic Republic of the Congo (DRC).
- Other names
- rVSV-BDBVrVSV-BDBV-GP
02
Targets
BDBV GP (Bundibugyo ebolavirus glycoprotein)
Beyond the preview
Go deeper on rVSV-BDBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rVSV-BDBV.